Literature DB >> 7524055

HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes.

B Y Perotti1, T Prueksaritanont, L Z Benet.   

Abstract

Despite the current use of a standard two-step enzyme immunoassay in the clinical monitoring of the immunosuppressant FK 506, the lack of specificity for the parent drug in this assay renders it unsuitable for drug metabolism studies. An HPLC assay has been developed for studying the metabolism of FK 506 in isolated hepatocytes and microsomal mixtures. This assay allows simultaneous measurement of the parent drug and two of its time dependent metabolites. Metabolism of this drug was studied in intact rat liver cells and rat liver microsomes. We have shown that the metabolites observed are products of phase 1 oxidation reactions. Correlation of the 6 beta-testosterone hydroxylase activity with the FK 506 metabolite (M1) initial formation rate is consistent with the belief that CYP 3A isozymes are involved in FK 506 metabolism in male rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524055     DOI: 10.1023/a:1018977707960

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  A whole blood FK 506 assay for the IMx analyzer.

Authors:  F C Grenier; J Luczkiw; M Bergmann; S Lunetta; M Morrison; D Blonski; K Shoemaker; M Kobayashi
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection.

Authors:  K Takada; M Oh-Hashi; H Yoshikawa; S Muranishi; M Nishiyama; H Yoshida; T Hata; H Tanaka
Journal:  J Chromatogr       Date:  1990-08-24

4.  Transport and metabolism of cyclosporine in isolated rat hepatocytes. The effects of lipids.

Authors:  T Prueksaritanont; M Koike; B A Hoener; L Z Benet
Journal:  Biochem Pharmacol       Date:  1992-05-08       Impact factor: 5.858

5.  Effect of FK-506 on human mixed lymphocyte reaction in vitro.

Authors:  T Kino; N Inamura; F Sakai; K Nakahara; T Goto; M Okuhara; M Kohsaka; H Aoki; T Ochiai
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes.

Authors:  D J Waxman; G A Dannan; F P Guengerich
Journal:  Biochemistry       Date:  1985-07-30       Impact factor: 3.162

8.  Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.

Authors:  K Iwasaki; T Shiraga; K Nagase; Z Tozuka; K Noda; S Sakuma; T Fujitsu; K Shimatani; A Sato; M Fujioka
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

9.  Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood.

Authors:  J N Murthy; Y Chen; V S Warty; R Venkataramanan; J G Donnelly; A Zeevi; S J Soldin
Journal:  Clin Chem       Date:  1992-07       Impact factor: 8.327

10.  FK 506 metabolism in male and female rat liver microsomes.

Authors:  B Y Perotti; N Okudaira; T Prueksaritanont; L Z Benet
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

View more
  2 in total

Review 1.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.